Recent Company News

• 02:31 AM ET Jun 15, 2026
  

  Bayer's AMBELVIST (gadoquatrane) receives FDA approval for contrast-enhanced MRI to detect and visualize lesions with abnormal vascularity in the central nervous system and non-CNS body regions (€36.19, 0.00)

• 03:18 AM ET Jun 11, 2026
  

  Alembic Pharmaceuticals receives USFDA tentative approval for ANDA Larotrectinib Capsules, 25 mg and 100Mg (INR 737.05, +0.55)

• 03:09 AM ET Jun 10, 2026
  

  Trump's pharma offensive puts Europe's drug pricing under the microscope:

• 06:49 AM ET Jun 05, 2026
  

  Bayer announces Phase III FIND‑CKD results show KERENDIA (finerenone) improved eGFR slope and reduced risk of a composite kidney-cardiovascular outcome in adults with non‑diabetic chronic kidney disease (€36.09, +0.53)

• 11:26 AM ET Jun 04, 2026
  

  FTC grants antitrust clearance for Bayer AG's acquisition of Perfuse Therapeutics (€35.45, +0.75)

• 10:46 AM ET Jun 04, 2026
  

  StreetAccount ESG Press Digest

• 08:55 AM ET Jun 04, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 09:21 AM ET Jun 03, 2026
  

  StreetAccount Summary - This Term's Notable Supreme Court Cases

• 08:29 AM ET Jun 03, 2026
  

  ESG Daily - Google ordered to provide AI training opt-out; EU to ease green spending rules

• 08:15 AM ET Jun 03, 2026
  

  StreetAccount Themes Headlines (3-Jun)